摘要
对３４例原发性肝癌（ＰＬＣ）患者外周血可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）、ＮＫ活性、Ｔ淋巴细胞亚群进行测定。结果：ＰＬＣ患者ｓＩＬ－２Ｒ水平明显高于健康对照组（Ｐ＜０．０１），ＮＫ活性、Ｔ淋巴细胞亚群ＣＤ３、ＣＤ４、ＣＤ４／ＣＤ比值均低于正常人（Ｐ＜０．０１），而ＣＤ８高于正常对照组（Ｐ＜０．０５）。Ⅱ、Ⅲ期ＰＬＣ患者ｓＩＬ－２Ｒ水平显著高于Ⅰ期患者（Ｐ＜０．０１）。ｓＩＬ－２Ｒ水平≥１０００ｕ／ｍｌ、５００～１０００ｕ／ｍｌ、＜５００ｕ／ｍｌ者６个月内的死亡率分别为８０．０％、２９．４％、０％。肝癌切除术后２周ｓＩＬ－２Ｒ水平较术前低（Ｐ＜０．０５），免疫治疗后４周ｓＩＬ－２Ｒ水平亦较治疗前低（Ｐ＜０．０５）。细胞免疫水平都有所改善。提示测定外周血ｓＩＬ－２Ｒ水平可作为ＰＬＣ的免疫状态、病情严重程度、疗效观察及预后估计的生物学指标。
Soluble interleukin-2 recepter(sIL-2R) levels,NK activity and T lymphocyte subpopulation in peripheral blood were determined in 34 cases of primary liver cancer(PLC). The results showed that the mean level of sIL-2R and CD8 in the patients with primary liver cancer were higher than that inhealth subjects (P<0. 01 or P<0. 05), NK activity and T lymphocyte subpopulation (CD3, CD4, CD4/CD8)in the patients with primary liver cancer were much lower than that in health subjects(F<0.01),sIL-2R levels in stage Ⅱ,Ⅲ patients with primary liver cancer were significantly higher than that in stage I (P<0. 01). The 6-month mortality rate in 3 groups of patients with sIL-2R level ≥1000u/ml,500- 1000u/ml,and <500u/ml were 80.0%, 29.4% and 0 respectively. sIL-2R levels were decreased (P<0. 05)two weeks after hepatectomy. The sIL-2R levels were also decreased (P< 0. 05)in patient with primary liver cancer 4 weeks after immune therapy,but the cell-mediated immunity was increased.It suggests that sIL-2R level determination in peripheral blood is a new biological marker for the assessment of the stage,the response to medical intervention, the prognosis and cell-mediated immunity in primary liver cancer.
关键词
原发性
肝癌
SIL-2R
Primary liver cancer Soluble interleukin-2 receptor
